Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3-targeting CAR-NK cells
- Development stage
- Preclinical
- Lead developer
- Osaka University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
B7-H3-targeting CAR-NK cells are an experimental allogeneic cellular immunotherapy designed for the treatment of various solid tumors. These natural killer (NK) cells are genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets B7-H3 (CD276), an immune checkpoint molecule that is highly overexpressed in many aggressive malignancies, including glioblastoma, neuroblastoma, and non-small cell lung cancer. Developed as an 'off-the-shelf' product, these cells can be derived from healthy donors or cord blood, offering a potential safety advantage over autologous CAR-T therapies by reducing the risk of graft-versus-host disease (GvHD) and cytokine release syndrome. Preclinical studies have demonstrated that these engineered NK cells exhibit potent, antigen-specific cytotoxicity against B7-H3-positive tumor cells, leading to significant antitumor effects and prolonged survival in xenograft models.
- Other names
- B7-H3-targeted CAR-NK cellsB-7-H3-targeted CAR-NK cellsB 7-H3-targeted CAR-NK cellsCD276-targeting CAR-NK cellsCD-276-targeting CAR-NK cellsCD 276-targeting CAR-NK cellsanti-B7-H3 CAR-NK cellsanti-B-7-H3 CAR-NK cellsanti-B 7-H3 CAR-NK cells
02
Targets
B7-H3
Beyond the preview
Go deeper on B7-H3-targeting CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3-targeting CAR-NK cells.